Stock 2696 SHANGHAI HENLIUS BIOTECH, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Shanghai Henlius Biotech, Inc.

Equities

2696

CNE100003N76

Delayed Hong Kong S.E.
Other stock markets
 11:58:13 2024-04-28 pm EDT 		5-day change 1st Jan Change
16.6 HKD +0.61% Intraday chart for Shanghai Henlius Biotech, Inc. +8.78% +19.42%
Apr. 26 Shanghai Henlius Biotech's Cancer Drug Gets the Nod from US FDA MT
Apr. 24 Shanghai Henlius Biotech Doses 1st Patient in Fibrosis Drug Clinical Study in China MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Shanghai Henlius Biotech, Inc. Announces First Subject Dosed in Phase 1 Clinical Study in Healthy Subjects of HLX6018 in Mainland China
CI
Henlius Biotech Gets Clearance for China Clinical Trial of Carcinoma Drug
MT
Shanghai Henlius Biotech, Inc. Announces Application for the Clinical Trial of HLX53 (Anti-TIGIT Fc Fusion Protein) in Combination with HANSIZHUANG (Serplulimab Injection) and HANBEITAI (Bevacizumab Injection) for the First-Line Treatment of Local Advanced or Metastatic Hepatocellular Carcinoma was Approved by the National Medical Products Administration
CI
Shanghai Henlius Biotech Denosumab Biosimilar HLX14 Meets Endpoint
MT
Shanghai Henlius Biotech, Inc Announces Phase 3 Comparative Clinical Study of Prolia® and Xgeva® Biosimilar Candidate HLX14 Met Primary Endpoints
CI
Phase 3 Trial of Shanghai Henlius Biotech’s Osteoporosis Drug Meets Primary Study Endpoints
MT
Shanghai Henlius Biotech, Inc. Announces International Multi-Centre Phase 3 Clinical Study of Biosimilar of Denosumab HLX14 for Treatment of Osteoporosis in Postmenopausal Women at High Risk for Fracture has Met Primary Study Endpoints
CI
Shanghai Henlius Biotech Turns to Profit in 2023
MT
Shanghai Henlius Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Shanghai Henlius Biotech, Inc. Announces the First Patient Has Been Dosed in A Phase 1 Clinical Study of Hlx42 for Injection
CI
Shanghai Henlius Biotech, Inc. Announces Application for Clinical Trial of HLX6018 (Recombinant Anti-GARP/TGF-1 Humanised Monoclonal Antibody Injection) Approved by the National Medical Products Administration
CI
Shanghai Henlius Biotech Expects Record Full-Year Profit
MT
Shanghai Henlius Biotech, Inc. Provides Unaudited Consolidated Earnings Guidance for the Year Ended December 31, 2023
CI
Shanghai Henlius Biotech, Inc. Announces Supplemental New Drug Applications of HANDAYUAN (Adalimumab Injection) for the New Indications Have Been Accepted by the National Medical Products Administration
CI
Shanghai Henlius Biotech, Inc. Announces Phase 1 Clinical Study of A Biosimilar of Denosumab HLX14 Successfully Completed
CI
Sermonix Pharmaceuticals Inc. and Shanghai Henlius Biotech, Inc. Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene
CI
Indonesia Grants Marketing Approval to Henlius Biotech's Small-Cell Lung Cancer Treatment
MT
Shanghai Henlius Biotech, Inc. Receives Fast Track Designation by the United States Food and Drug Administration
CI
Shanghai Henlius Biotech, Inc. Announces Dosing of First Subject in A Phase 1 Clinical Studyin Healthy Chinese Male Subjects of Ipilimumab Biosimilarhlx13 (Recombinant Anti-Ctla-4 Fully Human Monoclonalantibody Injection)
CI
China Accepts Henlius Application for New Indication of Cancer Drug
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 2696 Stock
  4. News Shanghai Henlius Biotech, Inc.
  5. Highlights